Hu C-P, Dandapat A, Liu Y, Hermonat PL, Mehta JL. Blockade of hypoxia-reoxygenation-mediated collagen type I expression and MMP activity by overexpression of TGF-␤1 delivered by AAV in mouse cardiomyocytes. Am J Physiol Heart Circ Physiol 293: H1833-H1838, 2007. First published June 22, 2007; doi:10.1152/ajpheart.00488.2007.-Transforming growth factor (TGF)-␤1 is one of the most pleiotropic and multifunctional peptides known. While the cardioprotective effect of TGF-␤1 during ischemia is well known, the specific role of TGF-␤1 in altering the cardiac remodeling process remains unclear. This study was designed to examine the regulation of hypoxia-reoxygenation-mediated collagen type I expression and activity of matrix metalloproteinases (MMPs) by overexpression of TGF-␤1 in cultured HL-1 mouse cardiomyocytes. TGF-␤1 was overexpressed in cardiomyocytes by transfection with adeno-associated virus (AAV)/TGF-␤ 1 Latent or with AAV/TGF-␤ 1 ACT (active TGF-␤1). Twenty-four hours of hypoxia followed by 3 h of reoxygenation (H-R) markedly enhanced (pro)collagen type I expression and activity of MMPs concomitant with an increase in reactive oxygen species (ROS) release and LOX-1 expression. Overexpression of TGF-␤1 reduced these alterations induced by H-R. TGF-␤1 overexpression also blocked H-R-mediated p38 and p44/42 MAPK activation. Transfection with AAV/TGF-␤ 1 ACT was superior to that with AAV/TGF-␤ 1 Latent . These data for the first time demonstrate that H-R induces signals for cardiac remodeling in cardiomyocytes and TGF-␤1 can modulate, possibly via antioxidant mechanism, these signals. These findings contribute to further understanding of the role of TGF-␤1 in the cardiac remodeling process.
transforming growth factor-␤1; HL-1 adult murine cardiomyocytes; metalloproteinases HEART FAILURE IS THE FINAL common pathway of various cardiovascular diseases, including myocardial ischemia. Alterations in extracellular matrix (ECM), including its structure and properties, are important pathological features of the failing heart; these pathological alterations are collectively known as cardiac remodeling. Coupled with a decrease in ECM degradation by proteinases, such as matrix metalloproteinases (MMPs) (11) , ECM deposition leads to cardiac fibrosis, common to both systolic and diastolic (especially the latter) heart failure (34) . Reactive fibrosis in the region remote from the area of myocardial infarct is clearly detrimental to ventricular function and contributes to adverse outcomes after myocardial infarction. Therefore, ECM is an important therapeutic target in the management of acute myocardial infarction and treatment of established heart failure.
Two major components of ECM are collagen types I and III, which play an important role in maintenance of structure and function of the heart (11, 34) . Collagen type I is usually present in the form of thick fibers with high tensile strength. Therefore, collagen type I is considered a major determinant of myocardial stiffness (34) . Besides fibroblasts (11, 34) , cardiac myocytes are also an important source of collagen type I (21, 30) .
Transforming growth factor (TGF)-␤ 1 is one of the most pleiotropic and multifunctional peptides known (23) . It has potent effects on many different cell types and is involved in a wide variety of biological processes (23) . The cellular actions of TGF-␤ 1 are dependent not only on the cell type, but also on its state of differentiation and the cytokine milieu (17) . While TGF-␤ 1 stimulates fibroblast-like cell growth, enhances collagen synthesis, and suppresses collagen degradation (23) , there are studies showing that this growth factor can also limit myocardial ischemia-reperfusion (I/R) injury in isolated rat cardiac myocytes and intact hearts (3, 16, 26, 36) . The specific effect of TGF-␤ 1 on the cardiac remodeling process following I/R, however, remains unclear. ACT that appears to be functionally relevant in the process of I/R (36) .
LOX-1 is a lectinlike receptor for oxidized low-density lipoprotein (ox-LDL) (24) . LOX-1 is involved in the genesis of oxidant stress and inflammation during myocardial I/R (19) . ox-LDL treatment enhances collagen formation in fibroblasts that can be blocked by LOX-1 antibody (14) . It has been reported that TGF-␤ 1 can regulate LOX-1 expression in vascular endothelial cells, smooth muscle cells, and macrophages (10, 27) .
The present study was conducted to examine three major hypotheses: 1) A brief period of hypoxia-reoxygenation (H-R) upregulates the signals for cardiac remodeling; 2) overexpression of TGF-␤ 1 reduces the signals for cardiac remodeling; and 3) TGF-␤ 1 overexpression can modulate LOX-1 and redoxsensitive signaling in cardiomyocytes.
MATERIALS AND METHODS

Generation of recombinant AAV/TGF-␤ 1
ACT , AAV/TGF-␤ 1 Latent , and AAV/Neo. Rat TGF-␤ 1 cDNA was generated as described previously (18) . To obtain TGF-␤ 1 ACT , site-directed mutagenesis of TGF-␤1 cDNA was performed with the GeneEditor in vitro site-directed mutagenesis system (Promega). Cysteine in positions 223 and 225 of TGF-␤1 mRNA was substituted with serine. The mutation resulted in TGF-␤ 1 protein in its biologically active form on secretion. Latent TGF-␤1 cDNA was acquired by amplification of high-fidelity PCR as described previously (31) . Rat TGF-␤1 cDNA was used as template. The latent TGF-␤ 1 cDNA is from nt1247 to nt1585. The mutant and latent TGF-␤ 1 cDNA were verified by gene sequencing.
Latent or mutant rat TGF-␤ 1 cDNA was inserted into adenoassociated virus type 2 (AAV2) vector dl6-95, as described for other AAV vectors (18) . Hereafter, the recombinant AAV vector will be referred to as AAV/TGF-␤ 1 Latent or AAV/TGF-␤ 1 ACT . The generation of AAV/Neo virus has been described previously (18) . The virus stocks were generated and titered by dot blot hybridization (18) . The titers were calculated to be ϳ1 ϫ 10 11 encapsidated genomes per milliliter.
Cell culture and AAV vector infection. HL-1 adult murine cardiomyocytes were a gift from Dr. W. C. Claycomb (Louisiana State University Health Science Center, New Orleans, LA) and were cultured (8) . In brief, HL-1 cells were grown at 37°C under 5% CO2 in fibronectin-gelatin-coated flasks containing Claycomb medium (JRH Biosciences) supplemented with 10% fetal bovine serum (JRH Biosciences), 100 U/ml penicillin, 100 g/ml streptomycin (Invitrogen), 2 mM L-glutamine (Invitrogen), and 0.1 mM norepinephrine (Sigma). To transfect the cultured cells, AAV vectors were added to cell culture dishes at a multiplicity of infection (MOI) of 10 4 and incubated with the cells for 72 h at 37°C in 5% CO 2-95% air. The infection efficiency was evaluated by AAV/green fluorescent protein (GFP) expression with fluorescent microscopy.
Exposure of cardiomyocytes to hypoxia-reoxygenation. After 72 h of AAV vector (or culture medium only) transfection, myocytes were exposed to H-R and divided into the following groups: control: myocytes were continuously incubated in 95% air-5% CO2; H-R ϩ Saline: myocytes were exposed to 24 h of hypoxia (95% N 2 and 5% CO 2, PO2 Ϸ 30 mmHg) followed by 3 h of reoxygenation (95% air and 5% CO 2); H-R ϩ AAV/Neo: myocytes were transfected with AAV/Neo and then exposed to H-R; H-R ϩ AAV/TGF-␤ 1 ACT : myocytes were infected with AAV/TGF-␤ 1 ACT and then exposed to H-R; H-R ϩ AAV/TGF-␤ 1 Latent : myocytes transfected with AAV/TGF-␤ 1 Latent were exposed to H-R. This degree of H-R has been shown to result in myocyte injury, including apoptosis and necrosis (36) . At the end of H-R, culture medium was collected for the determination of MMP activity, and myocytes were examined for measurement of reactive oxygen species (ROS) release and expression of specific proteins.
Measurement of MMP activity. MMP activity was measured by zymography (4) . Briefly, the culture medium was subjected to electrophoresis in polyacrylamide gels containing 0.1% gelatin under nonreducing conditions. The gels were soaked in 2.5% Triton X-100 for 1 h and washed with water for 1 h. The gels were then incubated in a developing buffer containing 50 mM Tris, pH 7.4, 5 mM CaCl2, and 0.02% sodium azide overnight at 37°C. The gels were then stained with Coomassie blue for 1 h and photographed. Protein preparation and analysis by Western blot. Cardiomyocytes were lysed in iced lysis buffer and centrifuged at 4,000 rpm for 15 min at 4°C. The lysate proteins (50 g/lane) were separated by SDS-PAGE (or 8% nondenatured PAGE for collagen I) and transferred to nitrocellulose membranes. After incubation in blocking solution (5% nonfat milk; Sigma), membranes were incubated with primary antibodies against mouse TGF-␤ 1 (v-, sc-146), procollagen I, collagen type I, LOX-1, mitogen-activated protein kinases (MAPKs; p38 and p44/42), or ␤-actin (source of antibodies: Santa Cruz) for overnight at 4°C. Membranes were washed and then incubated with 1:4,000 dilution specific secondary antibodies (Amersham) for 1 h at room temperature, and the membranes were washed and detected with the ECL system (Amersham). The relative densities of protein bands were analyzed by Scan-gel-it, and the relative density of each protein band was normalized to that of ␤-actin.
Statistical analysis. Data are expressed as means Ϯ SE. All values were analyzed by using one-way ANOVA and the Newman-KeulsStudent t-test. The significance level was chosen as P Ͻ 0.05.
RESULTS
AAV/GFP expression.
In pilot experiments, myocytes were treated with AAV/GFP vectors (MOI 0 -10 5 ) and incubated for 72 h at 37°C in 5% CO 2 -95% air. Since the most optimal (Ͼ90%) transfection was observed at an MOI of 10 4 (Fig. 1A) , this concentration was used in all subsequent experiments with AAV.
Overexpression of TGF-␤ 1 . After 72 h of AAV infection, cultured cardiomyocytes were exposed to H-R. At the end of H-R, the cells were harvested for Western blot analysis of total TGF-␤ 1 . As shown in Fig. 1B , total TGF-␤ 1 expression was markedly increased in AAV/TGF-␤ 1 ACT -or AAV/TGF-␤ 1 Latent -transfected cells, indicating successful delivery of the transgene into cardiomyocytes. In keeping with a previous study (26) , H-R itself induced the expression of TGF-␤ 1 . As expected, AAV/TGF␤ 1 -overexpressing cells had a much greater expression of TGF-␤ 1 . AAV/Neo had no effect on TGF-␤ 1 expression. We next examined whether AAV/TGF-␤ 1 transfection itself affects the basal expression of certain proteins. As shown in Fig. 1C , AAV/TGF-␤ 1 transfection itself had no effect on the basal expressions of (pro)collagen I, LOX-1, and p38 and p44/42 components of redox-sensitive MAPKs. We also found that AAV/TGF-␤ 1 transfection itself had no effect on the basal levels of ROS release and activity of MMP-2 and MMP-9 in the absence of H-R (data not shown).
AAV/TGF-␤ 1 transfection and collagen type I expression and MMP activity induced by H-R. H-R significantly increased the expression of procollagen I, collagen type I, and activity of MMP-2 and MMP-9 (vs. cells kept under control conditions) (P Ͻ 0.01, Fig. 2 ). Both TGF-␤ 1 Latent and TGF-␤ 1 ACT had a dramatic inhibitory effect on H-R-mediated upregulation of the expression of collagen type I and procollagen I and the activity of MMPs. TGF-␤ 1 ACT was superior to TGF-␤ 1 Latent in this regard.
It is of note that AAV/Neo transfection had no effect on H-R-mediated (pro)collagen type I expression and activity of MMPs Latent transfection significantly reduced DCF fluorescence despite H-R (P Ͻ 0.01; Fig. 3) . It has been shown that both I/R (19) and ROS (28) increase LOX-1 expression, and LOX-1 activation itself stimulates the formation of ROS (9) . In keeping with these studies, H-R in cardiomyocytes induced LOX-1 expression (P Ͻ 0.01 vs. control), which was inhibited by the overexpression of TGF-␤ 1 (Fig. 4) .
We next measured the expression of p38 and p44/42 MAPKs. As shown in Fig. 5 , the protein expression of p38 as well as p44/42 MAPKs was not altered during H-R. AAV/ TGF-␤ 1 transfection before H-R reduced the phosphorylation of both p38 and p44/42 MAPKs (P Ͻ 0.01). AAV/Neo transfection had no effect. Again, TGF-␤ 1 ACT was superior to TGF-␤ 1 Latent (P Ͻ 0.05).
DISCUSSION
This study confirmed all three of our hypotheses: 1) a brief period of H-R upregulates the signals for cardiac remodeling; 2) overexpression of TGF-␤ 1 reduces the signals for cardiac remodeling; and 3) TGF-␤ 1 overexpression can modulate LOX-1 and redox-sensitive signaling in cardiac myocytes.
In addition, we demonstrate that AAV2 is a very efficient vector for transfection of mouse cardiomyocytes with TGF-␤ 1 . Finally, TGF-␤ 1 ACT is superior to TGF-␤ 1 Latent with regard to modulation of H-R-mediated cardiac remodeling pathways. -transfected cells. Hypoxiareoxygenation (H-R) itself modestly enhanced the expression of TGF-␤1. AAV/Neo transfection had no effect on TGF-␤1 expression. C: effect of AAV/TGF-␤1 transfection itself on basal expression of specific proteins in the absence of H-R. AAV/TGF-␤1 transfection itself had no effect on the basal expressions of (pro)collagen I, LOX-1, and p38 and p44/42 mitogen-activated protein kinases (MAPKs). These data represent 3 separate experiments. p-p44/42 MAPK, p-p38 MAPK, phosphorylated p44/42 and p38 MAPKs. Presently there are three main viral vectors in use for gene therapy protocols: adenoviruses, retroviruses, and AAV. Among them, AAV-based vectors are naturally capable of efficient and stable gene delivery (13) . In fact, AAV is clearly the best virus to use for long-term gene transduction and expression (35) . Furthermore, neither wild-type nor recombinant AAV infection has been found to be associated with any significant pathology. A number of investigators have shown efficient transfection of genes in smooth muscle cells and fibroblasts with AAV (29, 37) . In our previous studies (18, 20) , we induced upregulation of IL-10 and TGF-␤ 1 ACT genes by using AAV2 by tail vein injection and showed sustained gene upregulation in vascular tissues of LDL receptor-knockout mice. The present study for the first time shows that mouse cardiomyocytes avidly take up AAV2.
The upregulation of (pro)collagen I in mouse cardiomyocytes following a brief period of H-R is a relatively novel observation. It is traditionally thought that the signals for cardiac remodeling appear late after ischemia. In previous studies, Kossmehl and colleagues (15) documented the release of carboxy-terminal propeptide of type I procollagen (PICP) in the perfusion fluid of porcine hearts as early as 2 h after coronary artery occlusion. This finding strongly hints that collagen synthesis had already commenced at this time. They also demonstrated release of fibronectin and osteopontin in porcine hearts after I/R, which are key players in cardiac remodeling along with collagen (15) . In earlier in vitro studies, we found that a brief exposure of cardiac fibroblasts to H-R results in enhanced collagen I synthesis (7). Takino et al. (33) in a recent study showed release of PICP in patients with myocardial infarction soon after deployment of reperfusion strategy. Release of PICP peaked at 2-3 wk after myocardial infarction and correlated with cardiac relaxation abnormality.
Thus our present observations of increased collagen signals early after H-R are in concordance with several previous studies (7, 15, 33) . The novelty of our study relates to the fact that cardiomyocytes also represent a potent source of collagen (21, 30) .
The present study showed that resting mouse cardiomyocytes express modest signals for (pro)collagen type I as well as activity of their regulatory MMPs. H-R increased the signals for (pro)collagen type I as well as activity of MMPs by two-to threefold. We believe that the increase in the activity of MMPs is an autoregulatory response to (pro)collagen type I signal as in cardiac fibroblasts (4, 7) . It is possible that MMPs contribute to cardiomyocyte injury, because previous studies have demonstrated limitation of cardiomyocyte injury by inhibitors of MMPs (3).
The intracellular signal for collagen expression appears to be release of ROS and activation of proinflammatory and prooxidant MAPKs, both p38 and p44/42. Again, this phenomenon appears to be akin to that in rat cardiac fibroblasts (4, 7) . In hearts exposed to I/R, there is strong evidence for the release of ROS during the early phase of reperfusion and subsequent activation of MAPKs and redox-sensitive transcription factors (22) . Previous in vitro studies have also documented that inhibition of ROS itself inhibits activation of MAPKs and reduces cardiomyocyte injury (5) .
We observed a marked upregulation of LOX-1 in cardiomyocytes after H-R. This observation is supported by previous in vitro and in vivo studies (19, 25) . LOX-1 is upregulated by ROS and can itself upregulate ROS generation in a positive feedback fashion (9, 28) . It is of note that cytokine TNF-␣ that is released during H-R can also induce LOX-1 expression (25) . LOX-1 activation in endothelial cells and fibroblasts enhances redox-sensitive signals, including activation of MAPKs and NF-B (6). TGF-␤ 1 is a pluripotent cytokine that has been shown to reduce H-R-mediated injury in rat cardiomyocytes as well as in intact rat hearts (3, 16, 26, 36) . We showed previously (36) that while TGF-␤ 1 Latent is upregulated during I/R, the conversion of TGF-␤ 1 Latent to its active form is reduced. The present study demonstrates that overexpression of this cytokine reduces the signals for cardiac remodeling in mouse cardiomyocytes exposed to H-R. Furthermore, both TGF-
Latent and TGF-␤ 1 ACT markedly attenuated H-R-associated intercellular signals, including ROS generation, LOX-1 expression, and activation of MAPKs. Most importantly, this study utilizing AAV-mediated overexpression strategy clearly demonstrates that TGF-␤ 1 ACT is much more potent than TGF-␤ 1 Latent in modulating signals for cardiac remodeling. TGF-␤ 1 is generally thought to be profibrotic in the heart. Nevertheless, arguments can be formulated for both pro-and antifibrotic roles for TGF-␤ 1 (12) . For example, TGF-␤ 1 may act primarily as a mitogen and as an inducer of cell migration and ECM synthesis. It is also possible that TGF-␤ 1 acts as a cytostatic and immunosuppressive agent, preventing fibroblast division and decreasing tissue inflammation. These activities would prevent or mitigate fibrous tissue formation. Furthermore, the limitation of I/R injury during the acute phase per se may abrogate the signals for long-term fibrosis. Obviously, studies need to be performed to examine the idea that cardiac remodeling in ischemic hearts is attenuated by overexpression of TGF-␤ 1 ACT over the long term. Such studies are currently under way in our laboratory. Figure 6 reflects our thinking on the pathways of procollagen I and collagen type I expression during H-R. We believe that ROS generation and LOX-1 expression are intertwined in a positive feedback fashion. LOX-1 activation stimulates MAPKs and related transcription factors, leading to upregulation of procollagen I and collagen type I expression. Increase in the activity of MMPs is an autoregulatory response to increased collagen formation. The critical role of LOX-1 in this process is supported by earlier observations that a specific antibody to LOX-1 blocks the expression of collagen I as well as MMPs (24, 14) . TGF-␤ 1 ACT acts as a protective cytokine by inhibiting ROS generation and LOX-1 expression/activation.
The mechanism of the effects of TGF-␤ 1 is diverse and has been reviewed in several recent publications (2, 12, 23) ; it involves activation of Smads and other signals including p38 MAPK, p44/42 MAPK, JNK, and TGF-␤-activated kinase 1 (TAK1) (2) . It has also been reported that regulation of membrane type 1 (MT1)-MMP/MMP-2 in cardiac fibroblasts by TGF-␤ 1 involves furin-convertase (32) . Whether any or all of these mechanisms are involved in the effects described in the present study is not known. Certainly, we have shown that overexpression of TGF-␤ 1 in mouse cardiomyocytes blocks H-R-mediated collagen type I expression and MMP activity mediated through ROS release and p38 and p44/42 MAPK activation.
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